Science Explorer Back to mapMap
Discussion
Institution · Hematology Oncology Associates

Most cited papers from Hematology Oncology Associates

Hematology Oncology Associates

What are the most cited papers from Hematology Oncology Associates?

The most cited paper from Hematology Oncology Associates is "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" (Ian F. Tannock, Ronald de Wit, William R. Berry et al., 2004), with 5,779 citations. Next come "Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer" (5,398) and "Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer" (1,863).

Showing 50 of 60 papers. Every paper with more than 169 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine 6 Oct 2004 5,779
2 Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond et al. · New England Journal of Medicine Open access 20 Oct 2005 5,398
3 Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer Steven J. Cohen, Cornelis J.A. Punt, Nicholas O. Iannotti et al. · Journal of Clinical Oncology Open access 30 Jun 2008 1,863
4 Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy Elizabeth Smith, Herbert Pang, Constance Cirrincione et al. · JAMA Open access 3 Apr 2013 1,024
5 Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial David J. Kuter et al. · The Lancet Feb 2008 872
6 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology Oct 2004 745
7 Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study David Morgan Thomas, Robert Mikael Henshaw, Keith M. Skubitz et al. · The Lancet Oncology 11 Feb 2010 716
8 Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study Sant P. Chawla, Robert Mikael Henshaw, Leanne L. Seeger et al. · The Lancet Oncology 15 Jul 2013 589
9 Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Arlene Chan et al. · The Lancet Oncology 12 Feb 2016 569
10 AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP James Bruce Bussel, David J. Kuter, James N. George et al. · New England Journal of Medicine Open access 18 Oct 2006 534
11 Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer Steven J. Cohen, Cornelis J.A. Punt, Nicholas O. Iannotti et al. · Annals of Oncology Open access 13 Mar 2009 508
12 Megestrol Acetate for the Prevention of Hot Flashes Charles L. Loprinzi, John C. Michalak, Susan K. Quella et al. · New England Journal of Medicine Open access 11 Aug 1994 506
13 Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer Mario E. Lacouture, Edith Peterson Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology 8 Feb 2010 485
14 Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 Thomas James Lynch, Taral Patel, Luke P. Dreisbach et al. · Journal of Clinical Oncology 26 Jan 2010 452
15 Superoxide generation by digitonin-stimulated guinea pig granulocytes. A basis for a continuous assay for monitoring superoxide production and for the study of the activation of the generating system. Harvey J. Cohen, Margaret E. Chovaniec · Journal of Clinical Investigation Open access Apr 1978 421
16 Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Neil P. Shah, Brian J. Skaggs, Susan Branford et al. · Journal of Clinical Investigation Open access 17 Aug 2007 417
17 Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Aaron Richard Hansen, Christophe Massard, Patrick Alexander Ott et al. · Annals of Oncology Open access 7 Jul 2018 370
18 Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy Ravi D. Rao, John C. Michalak, Jeff A. Sloan et al. · Cancer 12 Sep 2007 362
19 The symptom burden of cancer: Evidence for a core set of cancer‐related and treatment‐related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study Charles S. Cleeland, Fengmin Zhao, Victor Tsu-Shih Chang et al. · Cancer Open access 24 Sep 2013 319
20 Hypoxia-inducible Factor and Its Biomedical Relevance Eric L. Huang, H. Franklin Bunn · Journal of Biological Chemistry Open access May 2003 317
21 High-level expression of Egr-1 and Egr-1–inducible genes in mouse and human atherosclerosis Timothy A. McCaffrey, Chenzhong Fu, Baoheng Du et al. · Journal of Clinical Investigation Open access Mar 2000 298
22 Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer Frankie Ann Holmes, Stephen E. Jones, Joyce O’Shaughnessy et al. · Annals of Oncology Open access Jun 2002 294
23 Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial James L. Gulley, Arun Kumar Rajan, David Robert Spigel et al. · The Lancet Oncology Open access 31 Mar 2017 286
24 Radiation and immunotherapy: a synergistic combination Anusha K. Kalbasi, Carl H. June, Naomi Balzer Haas et al. · Journal of Clinical Investigation Open access 30 Jun 2013 281
25 Angiotensin II stimulates proliferation of normal early erythroid progenitors. Michal M. Mrug, Tomáš Stopka, Bruce A. Julian et al. · Journal of Clinical Investigation Open access Nov 1997 273
26 Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience Robert Lance Fine, Anthony P. Gulati, Benjamin A. Krantz et al. · Cancer Chemotherapy and Pharmacology 30 Jan 2013 259
27 Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma Ann Steward LaCasce, R. Gregory Bociek, Ahmed Sawas et al. · Blood Open access 27 Apr 2018 257
28 Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans Robert G. Maki, Rashid A. Awan, Richard H. Dixon et al. · International Journal of Cancer 30 Jul 2002 254
29 Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy George D. Demetri et al. · Journal of Clinical Oncology 29 May 2013 246
30 In vitro transformation of lymphoid cells by Abelson murine leukemia virus. Naomi E. Rosenberg, David Baltimore, Charles D. Scher · Proceedings of the National Academy of Sciences Open access May 1975 243
31 Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis Vishal Navnitray Ranpura, B. Pulipati, David L. Chu et al. · American Journal of Hypertension Review 25 Feb 2010 241
32 Geriatric Assessment-Identified Deficits in Older Cancer Patients With Normal Performance Status Trevor Augustus Jolly, Allison Mary Deal, Kirsten A. Nyrop et al. · The Oncologist Open access 12 Mar 2015 236
33 Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy Julie E. Hammack, John C. Michalak, Charles L. Loprinzi et al. · Pain Jul 2002 231
34 Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. Dan Douer, H. Phillip Koeffler · Journal of Clinical Investigation Open access Feb 1982 223
35 Human Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer Rafael Contreras-Galindo, Mark H. Kaplan, Philippe Leissner et al. · Journal of Virology Open access 17 Jul 2008 214
36 Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue Federico Innocenti, Gregory M. Cooper, Ian B. Stanaway et al. · PLoS Genetics Open access 26 May 2011 211
37 Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood Ewelina Marciniak, Harry David Bruce Wilson, RA Marlar · Blood Open access 1985 209
38 New molecularly targeted therapies for lung cancer Sophie Sun, Joan H. Schiller, Monica Spinola et al. · Journal of Clinical Investigation Open access Oct 2007 205
39 FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies Vivek Subbiah, Nicholas O. Iannotti, Martin E Gutierrez et al. · Annals of Oncology Open access 14 Feb 2022 203
40 Infusion Reactions Wendy H Vogel · Clinical journal of oncology nursing 29 Mar 2010 203
41 The soluble CD40 ligand sCD154 in systemic lupus erythematosus Kazunori Kato, Ernesto Santana-Sahagún, Laura Z. Rassenti et al. · Journal of Clinical Investigation Open access Oct 1999 198
42 Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis Yoshitaka Morita, Jian-Min Yang, Raj P. Gupta et al. · Journal of Clinical Investigation Open access 15 May 2001 194
43 Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial Ruben A. Mesa, Jason R. Gotlib, Vikas K Gupta et al. · Journal of Clinical Oncology Open access 20 Feb 2013 193
44 Defective anion transport and marked spherocytosis with membrane instability caused by hereditary total deficiency of red cell band 3 in cattle due to a nonsense mutation. Mutsumi Inaba, Ayumi Yawata, Ichiro Koshino et al. · Journal of Clinical Investigation Open access 15 Apr 1996 192
45 Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 Steven Peter Treon, Zachary R. Hunter, Jeffrey Matous et al. · Clinical Cancer Research Jun 2007 188
46 Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell–derived factor-1– and CD106 (VCAM-1)–dependent mechanism Jan A. Burger, Nathan J. Zvaifler, Nobuhiro Tsukada et al. · Journal of Clinical Investigation Open access Feb 2001 188
47 Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria WF Rosse · Blood Open access 15 Apr 1990 186
48 SOX9 drives WNT pathway activation in prostate cancer Fen Ma, Huihui Ye, Housheng Hansen He et al. · Journal of Clinical Investigation Open access 3 Apr 2016 186
49 Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis Sanjaykumar Hapani, Amna Falak Sher, David T. W. Chu et al. · Oncology Review 2010 186
50 Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Black Cohosh in the Management of Hot Flashes: NCCTG Trial N01CC1 Barbara A. Pockaj, James Gallagher, Charles L. Loprinzi et al. · Journal of Clinical Oncology Open access 16 Jun 2006 185

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.